Abstract: A protein is described that has an amino acid sequence characterized by at least 90% sequence identity with SEQ ID NO: 24, the protein being capable of recognizing a sequence consisting of 5?-GCCGAG-3? within the double-stranded DNA and cleaving the substrate predominantly at 21/19 nucleotides from the recognition site. A method is also described that utilizes the protein for creating a DNA tag for use as a unique identifier for paired end sequencing of DNA or serial analysis of gene expression.

Abstract: Recombinant DNA encoding NruI- and SboI-like restriction endonucleases and methylases and their amino acid sequences are provided as well as methods for expressing the enzymes in transformed host cells and purifying the enzymes.

Abstract: A recombinant BSA (rBSA) that (a) substantially lacks deoxyribonuclease activity as determined by incubating rBSA with linear DNA overnight and gel electrophoresis, (b) lacks animal viruses associated with animal-derived cell growth supplements; and (c) is capable of stabilizing DNA proteins is provided. Methods for making the rBSA and using it to stabilize enzymes are also provided.

Abstract: A method and system for the enzymatic treatment of a lipid containing feedstock comprises contacting the feedstock with a processing aid, then causing the feedstock to pass at a substantially constant flow rate through a treatment system comprising a plurality of enzyme-containing fixed bed reactors connected to one another in series. The fixed bed reactors can be individually serviceable, the flow rate of the feedstock remaining substantially constant through the system when one of the fixed bed reactors is taken off line for servicing. In the most preferred embodiment, the processing aid is a substantially moisture-free silica. The processing aid can be placed in one or more of the fixed bed reactors, disposed above the enzyme in the reactor, or it can be in a pre-treatment system which can comprise one or more reactors.

Abstract: The present invention relates generally to the field of molecular biology and regards various polynucleotides, polypeptides and methods that may be employed to enhance yield in transgenic plants. Specifically the transgenic plants may exhibit any one of the traits consisting of increased yield, increased tolerance to abiotic stress, increased cell growth and increased nutrient use efficiency.

Abstract: The present invention relates to a phytase which has at least 70% identity to a phytase derived from E. coli and comprises at least one modification as compared to this phytase. These phytase variants have modified, preferably improved, properties, such as thermostability, temperature profile, pH profile, specific activity, performance in animal feed, reduced protease sensibility, and/or an modified glycosylation pattern. The invention also relates to DNA encoding these phytases, methods of their production, as well as the use thereof, e.g. in animal feed and animal feed additives.

Abstract: Described are compositions and methods relating to the use of a glucoamylase in combination with a phytase in starch processing to reduce the levels of phytic acid in end-products.

Abstract: Disclosed are compositions comprising variants of alpha-amylase that have alpha-amylase activity and which exhibit altered properties relative to a parent AmyS-like alpha-amylase from which they are derived. The compositions comprise an additional enzyme such as a phytase. Also disclosed are methods of using the compositions, and kits related thereto.

Abstract: The present invention is directed to a composition comprising a vanadium-containing phosphatase inhibitor and a polyol. In the presence of the polyol the effect of the inhibitor is enhanced, even in the presence of chelating agents or reducing agents. The invention also concerns the use of the inventive composition for inhibiting a phosphatase, as well as kits comprising the composition.

Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.

Abstract: Diols produced in fermentation are processed in broth by esterification of the product diol with a carboxylic acid (e.g., fatty acid) and a catalyst (e.g., lipase) capable of esterifying the product diol, such as 1,3-propanediol, with the carboxylic acid to form the diol esters. The diol esters can be extracted from the broth, and the product diol recovered from the diol esters. The carboxylic acid can also serve as an extractant for removal of the diol esters from the fermentation medium.

Abstract: Site-specific Listeria integration vectors and methods for their use are provided. The subject vectors include a bacteriophage integrase gene and a bacteriophage attachment site, where in many embodiments the bacteriophage that is the source of these elements is a listeriophage. In certain embodiments, the subject vectors further include a multiple cloning site, where the multiple cloning site may further include a polypeptide coding sequence, e.g., for a heterologous antigen. The subject vectors and methods find use in a variety of different applications, including the study of Listeria species and the preparation of Listeria vaccines.

Abstract: Disclosed herein is site-directed mutagenesis of a cloned phyA gene employed to replaced cysteine residues involved in disulfide bridge formation with another amino acid. Also disclosed herein is an isolated mutant phytase comprising an amino acid sequence having at least 96 percent sequence identity to SEQ. ID. NO: 6 and containing a double-substitution amino acid residue substitution of residue 31 and residue 40 of SEQ. ID. NO: 6, wherein said isolated mutant phytase has phytase activity.

Abstract: Disclosed herein are variants enzymes that are structurally classified as CE-7 enzymes and have perhydrolysis activity. Also disclosed herein is a process for producing peroxycarboxylic acids from carboxylic acid esters using the aforementioned variant enzymes as well as methods and compositions comprising the variant enzymes. Further, disinfectant formulations comprising the peroxycarboxylic acids produced by the processes described herein are provided.

Abstract: A monomer of an I-CreI meganuclease variant wherein said monomer when in dimeric form binds and cleaves DNA.

Abstract: The present invention provides a novel nucleic acid sequence, designated ELIP, encoding a lipolytic enzyme and the corresponding encoded amino acid sequences. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding at least one novel lipolytic enzyme, recombinant lipolytic enzyme proteins and methods for producing the same.

Abstract: A method for obtaining at least one binding agent which binds a pharmaceutically active form of the compound with a higher specificity than a pharmaceutically inactive form of the compound is described by using special derivatives of said parent compound. The invention also pertains to the respectively created binding agents and derivatives. Furthermore, drug monitoring assays using said binding agents for monitoring pharmaceutically active forms of said parent compound are provided.

Abstract: The present invention provides a novel phosphatidic acid phosphatase gene. The object of the present invention can be solved by providing a nucleotide sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 7, SEQ ID NO: 4 or SEQ ID NO: 9, or SEQ ID NO: 5 or SEQ ID NO: 10; and an amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 6.

Abstract: The present invention relates to enzymes and processes. In particular, there is described an isolated polypeptide comprising the amino acid sequence corresponding to Citrobacter freundii phytase or a homologue, a modified form, a functional equivalent or an effective fragment thereof. There is also described a host cell transformed or transfected with a nucleic acid encoding a bacterial phytase enzyme or a modified form as well as the use of such a phytase or modified form in food or animal feed.

Abstract: Compositions, methods and a kit are described relating to a novel family of enzymes which preferentially bind to a hydroxymethylated cytosine or a glucosylated hydroxymethylated cytosine and cleave double-stranded DNA at a defined distance 3? of the recognition site to produce a cleavage fragment with a 1-3 base overhang.

Abstract: A monomer of an I-CreI meganuclease variant wherein said monomer when in dimeric form binds and cleaves DNA.

Abstract: Embodiments of the invention disclosed herein generally relate to anti-cocaine therapeutics. Specifically, some embodiments of the invention relate to highly efficient, thermostable, and long-lasting cocaine esterase (CocE) mutants that can protect against the toxic and reinforcing effects of cocaine in subjects. Provided herein are mutant CocE polypeptides displaying thermostable esterase activity. Also provided are methods of treating cocaine-induced conditions in a subject in need via administration of mutant CocE as well as methods for high-throughput screening of candidate esterase polypeptides.

Abstract: A reaction medium for enzyme-catalyzed reactions is provided, comprising an oil-in-water emulsion including water, an emulsifier, an oil phase and at least one interfacially active enzyme, where the emulsion is produced by the phase inversion temperature process and has a droplet size of 50 to 400 nm. A method for the enzyme-catalyzed esterification, transesterification or hydrolysis of fatty acid alkyl esters and/or triglycerides is also provided where the oil-in-water emulsion is used as the reaction medium.

Abstract: Embodiments of the present invention provide methods for targeted inactivation of viral genomes. In one embodiment, zinc-finger proteins in which DNA binding sites are altered such that they recognize and bind different, desired DNA sequences contained in hepatitis B virus (HBV) and that include nuclease domains are used for inactivation. Other embodiments for targeted inactivation of viral genomes use small nucleic acid molecules, such as short micro-RNA molecules or short hairpin RNA molecules capable of mediating RNA interference (RNAi) against the hepatitis B virus.

Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.

Abstract: The present invention features a recombinant DNA molecule which, upon expression in a prokaryotic or eukaryotic host cell, encodes a polypeptide having phytase activity. In preferred embodiments, the recombinant DNA molecule comprises a DNA sequence selected from DNA sequences which have been obtained by variations of the mature wild-type E. coli phytase sequence, wherein at least one amino acid at position 200 or position 207 is mutated as compared to the wild-type sequence, where the recombinant DNA molecule is, upon expression in a suitable host cell, associated with an increased activity of the thus encoded protein in the culture supernatant.

Abstract: The invention provides a method to prevent, inhibit or treat one or more neurological symptoms associated with a lysosomal storage disease in a mammal in need thereof, which includes intranasally administering to the mammal a composition comprising an effective amount of a lysosomal storage enzyme or a recombinant adeno-associated virus vector comprising an open reading frame encoding a lysosomal storage enzyme. Also provided are compositions and devices useful in the methods.

Abstract: The present invention relates to an in vitro method of diagnosis of a Plasmodium infection in a subject, by measuring the serum concentration of at least one secreted phospholipase A2 selected from the group consisting of GIIF, GV and GX sPLA2s, in said subject, from a blood sample. It also relates to a kit for carrying out said method and pharmaceutical compositions comprising a recombinant mammal GIIF, GV or GX sPLA2 or a combination thereof.

Abstract: Rationally-designed LAGLIDADG meganucleases and methods of making such meganucleases are provided. In addition, methods are provided for using the meganucleases to generate recombinant cells and organisms having a desired DNA sequence inserted into a limited number of loci within the genome, as well as methods of gene therapy, for treatment of pathogenic infections, and for in vitro applications in diagnostics and research.

Abstract: An improved saccharification process comprises the use of a glucoamylase and at least one cellulase. The improved saccharification process results in improved yields of fermentations products, such as ethanol. In one embodiment, the improved saccharification process results in an increased yield of up to 0.5% to 1% ethanol using commercially available cellulases. Also provided are improved simultaneous saccharification and fermentation (SSF) processes, and compositions comprising a liquefied starch slurry, a glucoamylase, and a cellulase.

Abstract: Provided herein are methods of integrating one or more exogenous nucleic acids into one or more selected target sites of a host cell genome. In certain embodiments, the methods comprise contacting the host cell genome with one or more integration polynucleotides comprising an exogenous nucleic acid to be integrated into a genomic target site, and a nuclease capable of causing a double-strand break near or within the genomic target site.

Abstract: A method of identifying a biofilm that includes non-typeable Haemophilus influenza (NTHi) including a step of screening a sample for the presence of one or more biofilm-specific proteins that are expressed by NTHi. In some cases, an NTHi biofilm-related disease in a subject is diagnosed. Also disclosed are protein microarrays for screening biofilm-specific proteins in a sample, formulations comprising one or more biofilm-specific proteins or fragments thereof, and methods for inducing an immune response in a patient against a biofilm-related infection.

Abstract: The present disclosure relates, according to some embodiments, to methods of increasing viral resistance in a plant, methods of increasing transgene expression in a plant, and methods of suppressing expression of a native gene in a plant. In some embodiments, the disclosure also relates to polypeptides involved in post-translational gene silencing (PTGS), for e.g., a protein active in PTGS or a suppressor of PTGS. The disclosure further relates to transgenic plant cells in which PTGS is altered (e.g., enhanced or suppressed) according to some embodiments.

Abstract: The inventors have developed improved polypeptides by substituting or deleting specified amino acids in fungal lipolytic enzymes. More particularly, the polypeptides result in a reduction of dough stickiness when they are added to a dough. The polypeptides may particularly have activity on polar lipids.

Abstract: The present invention is directed toward the delivery of toxic agents to pathogenic cells, particularly cancer cells. In some embodiments, the toxic agent is a human ribonuclease or similar agent that is toxic to cells.

Abstract: The invention provides hydrolases, polynucleotides encoding them, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides, e.g., enzymes, having a hydrolase activity, e.g., an esterase, acylase, lipase, phospholipase (e.g., phosphlipase A, B, C and D activity, patatin activity, lipid acyl hydrolase (LAH) activity) or protease activity, including thermostable and thermotolerant hydrolase activity, and polynucleotides encoding these enzyme, and making and using these polynucleotides and polypeptides. The hydrolase activities of the polypeptides and peptides of the invention include esterase activity, lipase activity (hydrolysis of lipids), acidolysis reactions (to replace an esterified fatty acid with a free fatty acid), transesterification reactions (exchange of fatty acids between triglycerides), ester synthesis, ester interchange reactions, phospholipase activity and protease activity (hydrolysis of peptide bonds).

Abstract: The present invention relates to alpha-amylase variants, polynucleotides encoding the variants and nucleic acid constructs, vectors, and host cells comprising the polynucleotides, and methods of using the variant enzymes.

Abstract: Described herein is the creation and use of Thermotoga-E. coli shuttle vectors; an embedded cultivation method that greatly simplifies the cultivation methods for Thermotoga previously used; and the subcloning, characterization, and use of a Thermotoga Restriction-modification system.

Abstract: The invention provides polypeptides, including enzymes, structural proteins and binding proteins, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. Polypeptides, including enzymes and antibodies, and nucleic acids of the invention can be used in industrial, experimental, food and feed processing, nutritional and pharmaceutical applications, e.g., for food and feed supplements, colorants, neutraceuticals, cosmetic and pharmaceutical needs.

Abstract: Rationally-designed LAGLIDADG meganucleases and methods of making such meganucleases are provided. In addition, methods are provided for using the meganucleases to generate recombinant cells and organisms having a desired DNA sequence inserted into a limited number of loci within the genome, as well as methods of gene therapy, for treatment of pathogenic infections, and for in vitro applications in diagnostics and research.

Abstract: The invention provides a non-naturally occurring microbial organism having an adipate, 6-aminocaproic acid or caprolactam pathway. The microbial organism contains at least one exogenous nucleic acid encoding an enzyme in the respective adipate, 6-aminocaproic acid or caprolactam pathway. The invention additionally provides a method for producing adipate, 6-aminocaproic acid or caprolactam. The method can include culturing an adipate, 6-aminocaproic acid or caprolactam producing microbial organism, where the microbial organism expresses at least one exogenous nucleic acid encoding an adipate, 6-aminocaproic acid or caprolactam pathway enzyme in a sufficient amount to produce the respective product, under conditions and for a sufficient period of time to produce adipate, 6-aminocaproic acid or caprolactam.

Abstract: The invention relates to the isolation, characterization and expression of DNA fragments encoding sphingomyelinases D from three species of Loxosceles genus spiders, namely L. boneti, L reclusa and L. laeta, and the toxoids thereof. The invention also relates to the production of active sphingomyelinases D and the toxoids thereof using recombinant means and to the use of same as an immunogen for the production in vertebrates of antibodies that neutralise the corresponding venom and the respective fragments F(ab?)2. The invention further relates to the use of recombinant sphingomyelinases D as part of an antigen matrix which can be used in the immunopurification of antibodies and the fragments thereof or as part of any diagnostic device used to obtain clinical confirmation that the causal agent of poisoning in a patient is a spider of the Loxosceles genus.

Abstract: Method of preparing I-CreI meganuclease variants having a modified cleavage specificity, variants obtainable by said method and their applications either for cleaving new DNA target or for genetic engineering and genome engineering for non-therapeutic purposes. Nucleic acids encoding said variants, expression cassettes comprising said nucleic acids, vectors comprising said expression cassettes, cells or organisms, plants or animals except humans, transformed by said vectors.

Abstract: A method of treating a mammal prophylactically to prevent neoplastic development comprises administering to the mammal a therapeutic vaccine comprising venom and at least one adjuvant. The method optionally further comprises administering to the mammal at least one other therapeutically effective agent, e.g., an anti-inflammatory agent.

Abstract: Meganuclease variants which cleave at least one target in the provirus of a retrovirus and in particular which cleave the genomic insertion of the provirus. The present invention in particular relates to meganuclease variants which cleave the provirus of the Human Immunodeficiency Virus genome following genomic insertion. Vector encoding such variants, as well as to a cell or multi-cellular organism modified by such a vector and use of said meganuclease variants and derived products for genome engineering and for in vivo and ex vivo (gene cell therapy) genome therapy.

Abstract: The present invention relates to alpha-amylase variants, polynucleotides encoding the variants and nucleic acid constructs, vectors, and host cells comprising the polynucleotides, and methods of using the variant enzymes.

Abstract: The present invention relates to the discovery of a novel restriction/modification system in Caldicellulosiruptor bescii. The discovered restriction enzyme is a HaeIII-like restriction enzyme that possesses a thermophilic activity profile. The restriction/modification system also includes a methyltransferase, M.CbeI, that methylates at least one cytosine residue in the CbeI recognition sequence to m4C. Thus, the invention provides, in various aspects, isolated CbeI or M.CbeI polypeptides, or biologically active fragments thereof; isolated polynucleotides that encode the CbeI or M.CbeI polypeptides or biologically active fragments thereof, including expression vectors that include such polynucleotide sequences; methods of digesting DNA using a CbeI polypeptide; methods of treating a DNA molecule using a M.CbeI polypeptide; and methods of transforming a Caldicellulosiruptor cell.

Abstract: Promoter regions associated with the Yarrowia lipolytica esterase/lipase (EL1) gene are disclosed and have been found to be particularly effective for the expression of heterologous genes in yeast. These promoter regions will be useful for driving high-level expression of genes involved in the production of omega-3 and omega-6 fatty acids.

Abstract: Disclosed herein are methods and compositions for increasing yield of induced pluripotent stem cells (iPSCs).

Abstract: The present invention is directed to a composition comprising a vanadium-containing phosphatase inhibitor and a polyol. In the presence of the polyol the effect of the inhibitor is enhanced, even in the presence of chelating agents or reducing agents. The invention also concerns the use of the inventive composition for inhibiting a phosphatase, as well as kits comprising the composition.